At first, it was tentative. But now almost all parts of the U.S. healthcare system are racing to adopt some form of ...

Expedited regulatory paths transform colorectal cancer treatment, enhancing access but creating challenges in clinical evidence and payer decisions.

The Chinorec trial reveals that combining Yervoy and Opdivo with chemoradiotherapy is safe for rectal cancer, though response rates remain unchanged.

A new study confirms ICD-10 code L80's high accuracy in identifying vitiligo, especially when combined with treatment data, enhancing clinical research.

The exact cause of amyotrophic lateral sclerosis (ALS) has long remained a mystery, but new research demonstrates that there ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Novo Nordisk has a factor VIII mimetic in a phase 3 trial, and a Chinese company is forging ahead with its gene therapy ...

In July 2025, the FDA granted priority review for TAR-200 as therapy for patients with high-risk nonmuscle invasive bladder ...

An expert discusses how systemic treatments for vitiligo often have better patient adherence than topical treatments, though ...

Promoting interdisciplinary collaboration via molecular tumor boards and shared decision-making frameworks might improve the ...

Humana announces its 2026 Medicare Advantage and prescription drug plans, focusing on stable benefits, preventive care and ...

Aetna has released the details of its Medicare Advantage plans for 2026, which focus on preventative care and drug cost ...